BioMarin Appoints Timothy Walbert to Board of Directors
BioMarin welcomes biotech veteran Timothy Walbert to its Board to drive innovation and patient-focused growth.
BioMarin Pharmaceutical has announced the appointment of Timothy P. Walbert to its Board of Directors, effective February 24, 2025. Walbert, former chairman and CEO of Horizon Therapeutics, brings over 30 years of leadership in biopharmaceuticals, having played key roles in companies like Amgen, AbbVie, and Pfizer. His experience in commercializing medicines and driving strategic growth makes him a valuable addition as BioMarin continues its mission of delivering breakthrough therapies for genetically defined conditions.
Alexander Hardy, BioMarin’s president and CEO, highlighted Walbert’s deep industry expertise and commitment to patient-centered innovation. "Tim’s proven leadership in bringing life-changing treatments to market aligns perfectly with our vision," said Hardy. Walbert, currently a senior advisor at Amgen, expressed enthusiasm about joining BioMarin at a pivotal time. "I look forward to contributing to BioMarin’s focus on innovation, growth, and value creation while keeping patients at the center of everything we do," he shared.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Altro da Pharma News
Tutti gli articoli →
Medicus Pharma presenta all’FDA il protocollo di fase 2b/3 per Teverelix
Fresenius Kabi Riceve una Lettera di Richiamo dalla FDA dopo Fallimenti nelle Indagini sul Processo Asettico presso lo Stabilimento di Melrose Park
Discussion